These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35921199)

  • 1. Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression.
    Juárez-Fernández M; Goikoetxea-Usandizaga N; Porras D; García-Mediavilla MV; Bravo M; Serrano-Maciá M; Simón J; Delgado TC; Lachiondo-Ortega S; Martínez-Flórez S; Lorenzo Ó; Rincón M; Varela-Rey M; Abecia L; Rodríguez H; Anguita J; Nistal E; Martínez-Chantar ML; Sánchez-Campos S
    Hepatology; 2023 May; 77(5):1654-1669. PubMed ID: 35921199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of global PTP1B deficiency on the gut barrier permeability during NASH in mice.
    Rubio C; Puerto M; García-Rodríquez JJ; Lu VB; García-Martínez I; Alén R; Sanmartín-Salinas P; Toledo-Lobo MV; Saiz J; Ruperez J; Barbas C; Menchén L; Gribble FM; Reimann F; Guijarro LG; Carrascosa JM; Valverde ÁM
    Mol Metab; 2020 May; 35():100954. PubMed ID: 32244182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease.
    Petrov PD; García-Mediavilla MV; Guzmán C; Porras D; Nistal E; Martínez-Flórez S; Castell JV; González-Gallego J; Sánchez-Campos S; Jover R
    Mol Nutr Food Res; 2019 Oct; 63(20):e1900487. PubMed ID: 31322321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.
    Mouries J; Brescia P; Silvestri A; Spadoni I; Sorribas M; Wiest R; Mileti E; Galbiati M; Invernizzi P; Adorini L; Penna G; Rescigno M
    J Hepatol; 2019 Dec; 71(6):1216-1228. PubMed ID: 31419514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIRT3 Deficiency Promotes High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Correlation with Impaired Intestinal Permeability through Gut Microbial Dysbiosis.
    Chen M; Hui S; Lang H; Zhou M; Zhang Y; Kang C; Zeng X; Zhang Q; Yi L; Mi M
    Mol Nutr Food Res; 2019 Feb; 63(4):e1800612. PubMed ID: 30525304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice.
    Porras D; Nistal E; Martínez-Flórez S; Olcoz JL; Jover R; Jorquera F; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Mol Nutr Food Res; 2019 Apr; 63(8):e1800930. PubMed ID: 30680920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbiota-mediated generation of saturated fatty acids elicits inflammation in the liver in murine high-fat diet-induced steatohepatitis.
    Yamada S; Kamada N; Amiya T; Nakamoto N; Nakaoka T; Kimura M; Saito Y; Ejima C; Kanai T; Saito H
    BMC Gastroenterol; 2017 Nov; 17(1):136. PubMed ID: 29187142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut-Liver Axis.
    Yang C; Wan M; Xu D; Pan D; Xia H; Yang L; Sun G
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.
    Ye JZ; Li YT; Wu WR; Shi D; Fang DQ; Yang LY; Bian XY; Wu JJ; Wang Q; Jiang XW; Peng CG; Ye WC; Xia PC; Li LJ
    World J Gastroenterol; 2018 Jun; 24(23):2468-2481. PubMed ID: 29930468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qingrequzhuo capsule alleviated methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice through regulating gut microbiota, enhancing gut tight junction and inhibiting the activation of TLR4/NF-κB signaling pathway.
    Lv S; Zhang Z; Su X; Li W; Wang X; Pan B; Li H; Zhang H; Wang Y
    Front Endocrinol (Lausanne); 2022; 13():1106875. PubMed ID: 36743916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis.
    Schneider KM; Mohs A; Kilic K; Candels LS; Elfers C; Bennek E; Schneider LB; Heymann F; Gassler N; Penders J; Trautwein C
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary fat and gut microbiota interactions determine diet-induced obesity in mice.
    Kübeck R; Bonet-Ripoll C; Hoffmann C; Walker A; Müller VM; Schüppel VL; Lagkouvardos I; Scholz B; Engel KH; Daniel H; Schmitt-Kopplin P; Haller D; Clavel T; Klingenspor M
    Mol Metab; 2016 Dec; 5(12):1162-1174. PubMed ID: 27900259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
    Wang P; Wang J; Li D; Ke W; Chen F; Hu X
    J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of the Caspases 1/11 Modulates Liver Global Lipid Profile and Gut Microbiota in High-Fat-Diet-Induced Obese Mice.
    de Sant'Ana LP; Ribeiro DJS; Martins AMA; Dos Santos FN; Corrêa R; Almeida RDN; Eberlin MN; Maurice CF; Magalhães KG
    Front Immunol; 2019; 10():2926. PubMed ID: 31998283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis.
    Li H; Xi Y; Xin X; Tian H; Hu Y
    Biomed Pharmacother; 2020 Apr; 124():109915. PubMed ID: 31986416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lingguizhugan decoction improves non-alcoholic steatohepatitis partially by modulating gut microbiota and correlated metabolites.
    Zhu M; Wang X; Wang K; Zhao Z; Dang Y; Ji G; Li F; Zhou W
    Front Cell Infect Microbiol; 2023; 13():1066053. PubMed ID: 36779187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis.
    Chiu CC; Ching YH; Li YP; Liu JY; Huang YT; Huang YW; Yang SS; Huang WC; Chuang HL
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29113135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Val-Val-Tyr-Pro protects against non-alcoholic steatohepatitis in mice by modulating the gut microbiota and gut-liver axis activation.
    Xie X; Zhang L; Yuan S; Li H; Zheng C; Xie S; Sun Y; Zhang C; Wang R; Jin Y
    J Cell Mol Med; 2021 Feb; 25(3):1439-1455. PubMed ID: 33400402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.